NASDAQ:ATRCAtriCure Stock Price, Forecast & News

AtriCure's stock was trading at $35.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATRC shares have increased by 27.4% and is now trading at $44.94. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AtriCure.

AtriCure is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for AtriCure.

AtriCure Inc. (NASDAQ:ATRC) announced its earnings results on Wednesday, April, 29th. The medical device company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.01. The medical device company had revenue of $53.20 million for the quarter, compared to the consensus estimate of $54.13 million. AtriCure had a negative return on equity of 19.19% and a negative net margin of 19.98%. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.20) earnings per share. View AtriCure's earnings history.

AtriCure issued an update on its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $53.2-53.2 million, compared to the consensus revenue estimate of $59.84 million.

9 brokers have issued 12-month target prices for AtriCure's shares. Their forecasts range from $30.00 to $56.00. On average, they anticipate AtriCure's stock price to reach $46.22 in the next year. This suggests a possible upside of 2.9% from the stock's current price. View analysts' price targets for AtriCure.

Media coverage about ATRC stock has trended negative this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AtriCure earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAtriCure.

Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), Allergan (AGN), CVS Health (CVS), Walt Disney (DIS) and Intel (INTC).

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.75%), Wellington Management Group LLP (5.06%), Champlain Investment Partners LLC (4.23%), Invesco Ltd. (3.83%), Fred Alger Management LLC (3.15%) and GW&K Investment Management LLC (2.67%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View institutional ownership trends for AtriCure.

ATRC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Peregrine Capital Management LLC, BlackRock Inc., GW&K Investment Management LLC, The Manufacturers Life Insurance Company , Paradigm Capital Management Inc. NY, DAFNA Capital Management LLC, and Eagle Asset Management Inc.. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, and Michael H Carrel. View insider buying and selling activity for AtriCure.

ATRC stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Invesco Ltd., Orbimed Advisors LLC, Champlain Investment Partners LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Nuveen Asset Management LLC, and Granahan Investment Management Inc. MA. View insider buying and selling activity for AtriCure.

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ATRC stock can currently be purchased for approximately $44.94.

AtriCure has a market capitalization of $1.80 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe.

The official website for AtriCure is www.atricure.com.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.